RSCM
NGM

Rock Springs Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Rock Springs Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-364,800
Closed -$10.6M – 163
2021
Q1 		$10.6M Buy
364,800
+4,300
+1% +$120K 0.23% 108
2020
Q4 		$10.9M Buy
360,500
+46
+0% +$1.01K 0.23% 109
2020
Q3 		$5.74M Buy
360,454
+3,045
+0.9% +$55.5K 0.15% 123
2020
Q2 		$7.05M Buy
357,409
+6,309
+2% +$121K 0.19% 116
2020
Q1 		$4.33M Hold
351,100
– – 0.18% 105
2019
Q4 		$6.49M Hold
351,100
– – 0.21% 101
2019
Q3 		$4.86M Hold
351,100
– – 0.19% 105
2019
Q2 		$5.14M Buy
+351,100
New +$5.14M 0.19% 102

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Rock Springs Capital Management's NGM Position: Q2 2021 in Review

Rock Springs Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2021, closing a stake of 364,800 shares — an estimated $10.6M sold.

Rock Springs Capital Management first reported a position in NGM in Q2 2019 and held it in 8 quarters. The position peaked at $10.9M in Q4 2020. 107 funds tracked by Wall St. Rank hold NGM as of Q2 2021.

  • Rock Springs Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Rock Springs Capital Management sold 364,800 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $10.6M.
  • Rock Springs Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Rock Springs Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $10.9M in Q4 2020.
  • 107 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Rock Springs Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.